Thyrocare Technologies Limited has announced the launch of its state-of-the-art genomics laboratory in Navi Mumbai. With this launch, Thyrocare is expanding its portfolio with a new range of speciality tests in genomics, powered by a state-of-the-art facility equipped with advanced next-generation sequencing technologies and supported by robust bioinformatics and data interpretation capabilities.
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence.
Mr Rahul Guha, MD & CEO, Thyrocare and API Holdings, said, “The launch of our genomics laboratory marks a significant step forward in this journey, as we expand into advanced, high-impact areas of testing. As healthcare continues to move towards predictive and preventive care, genomics will play a critical role in enabling early insights and better clinical decision-making. With this expansion, we aim to make advanced genomics testing more accessible and affordable while continuing to build on our proven model of high-throughput, quality-driven diagnostics.”
Speaking on the launch of the new genomics lab, Dr Ramesh Kinha, COO, Thyrocare, said, “Backed by Thyrocare’s scale, automation, and strong credibility in routine diagnostics, we are now enabling high-quality and affordable speciality testing across India. This new genomics laboratory allows us to bring precision diagnostics closer to clinicians and patients while maintaining consistency, accuracy, and reliability in every report.”
